Co-Founder, President, CEO & Director Presentation Good afternoon. I'm Ray. I'm part of the Medtech research team here at Bank of America, and it's my pleasure to introduce Paul Badawi from Sight Sciences here today. Welcome, Paul. Thanks for being here. Paul Badawi We are an interventional eye care leader. We are active, commercially active in 2 large growing segments in eye care anterior segment, glaucoma and dry eye disease. Glaucoma is the world's leading cause of irreversible blindness and dry eye dise ...

Sight Sciences (NasdaqGS:SGHT) 2026 Conference May 13, 2026 06:15 PM ET Company Participants Our label allows us to educate on all of these benefits of OMNI in combo cataract, both mild, moderate, and severe, as well as standalone, mild, moderate, and severe. They're all significant opportunities today. Most of MIGS is done in combination with cataract. You see the that mild to moderate combo cataract, about a $4 billion opportunity. There's an opportunity for expanding that combo cataract market the standa ...